From: Design and synthesis of chalcone derivatives as potential non-purine xanthine oxidase inhibitors
Compound | R1 | R2 | R3 | R4 | R5 | R6 | IC50 (μM) |
---|---|---|---|---|---|---|---|
3 | H | H | H | H | OH | OH | 40.9 |
4 | OH | H | OH | H | H | H | >100 |
5 | OH | H | OH | H | OH | OH | 4.3 |
6 | OH | H | OH | OH | H | OH | 16.3 |
7 | OMe | H | OH | H | OH | OH | 3.9 |
8 | OH | H | OH | H | OH | OMe | 36.7 |
9 | OH | H | OH | H | OMe | OMe | >100 |
10 | OH | H | OMe | H | OH | OH | 19.2 |
11 | OMe | H | OMe | H | OH | OH | 2.5 |
12 | OH | H | OH | OH | H | OMe | 21.8 |
13 | OH | Caffeoyl | OMe | H | OH | OH | 2.4 |
14 | H | H | H | H | OH | OMe | >100 |
15 | H | H | H | H | OMe | OMe | >100 |
16 | OH | H | OMe | H | OMe | OMe | >100 |
17 | OH | H | OAc | H | OAc | OAc | >100 |
18 | H | H | H | H | H | H | >100 |
Allopurinol | 2.5 |